Literature DB >> 12379775

Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen.

Ian Matthews1, Gary Sims, Serena Ledwidge, David Stott, David Beeson, Nick Willcox, Angela Vincent.   

Abstract

The weakness in myasthenia gravis (MG) is mediated by autoantibodies against adult muscle acetylcholine receptors (AChR) at the neuromuscular junction; most of these antibodies also bind to fetal AChR, which is present in the thymus. In rare cases, babies of mothers with MG, or even of asymptomatic mothers, develop a severe developmental condition, arthrogryposis multiplex congenita, caused by antibodies that inhibit the ion channel function of the fetal AChR while not affecting the adult AChR. Here we show that these fetal AChR inhibitory antibodies are significantly more common in females sampled after pregnancy than in those who present before pregnancy, suggesting that they may be induced by the fetus. Moreover, we were able to clone high-affinity combinatorial Fab antibodies from thymic cells of two mothers with MG who had babies with arthrogryposis multiplex congenita. These Fabs were highly specific for fetal AChR and did not bind the main immunogenic region that is common to fetal and adult AChR. The Fabs show strong biases to VH3 heavy chains and to a single Vkappa1 light chain in one mother. Nevertheless, they each show extensive intraclonal diversification from a highly mutated consensus sequence, consistent with antigen-driven selection in successive steps. Collectively, our results suggest that, in some cases of MG, initial immunization against fetal AChR is followed by diversification and expansion of B cells in the thymus; maternal autoimmunity will result if the immune response spreads to the main immunogenic region and other epitopes common to fetal and adult AChR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379775     DOI: 10.1097/01.lab.0000032379.63784.9c

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  12 in total

1.  Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Authors:  Maria I Leite; Margaret Jones; Philipp Ströbel; Alexander Marx; Ralf Gold; Erik Niks; Jan J G M Verschuuren; Sonia Berrih-Aknin; Francesco Scaravilli; Aurea Canelhas; B Paul Morgan; Angela Vincent; Nick Willcox
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.

Authors:  S Gattenlöhner; H Jörissen; M Huhn; A Vincent; D Beeson; S Tzartos; A Mamalaki; B Etschmann; H K Muller-Hermelink; E Koscielniak; S Barth; A Marx
Journal:  J Biomed Biotechnol       Date:  2010-02-24

3.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

4.  [Adoptive T-cell therapy of rhabdomyosarcoma].

Authors:  K Simon-Keller; A Paschen; S Eichmüller; S Gattenlöhner; S Barth; E Koscielniak; I Leuschner; P Stöbel; A Hombach; H Abken; A Marx
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Increased risk for clinical onset of myasthenia gravis during the postpartum period.

Authors:  Marion I Boldingh; Angelina H Maniaol; Cathrine Brunborg; Harald Weedon-Fekjær; Jan J G M Verschuuren; Chantal M E Tallaksen
Journal:  Neurology       Date:  2016-10-21       Impact factor: 9.910

6.  Arthrogryposis multiplex congenita (AMC), a hereditary disease in swine, maps to chromosome 5 by linkage analysis.

Authors:  Sem Genini; Massoud Malek; Spela Spilar; Trung Thanh Nguyen; Frédéric Ménétrey; Stefen Gebert; Christian Hagger; Stefan Neuenschwander; Haja N Kadarmideen; Gerald Stranzinger; Peter Vögeli
Journal:  Mamm Genome       Date:  2004-11       Impact factor: 2.957

7.  John Newsom-Davis: clinician-scientist and so much more.

Authors:  Angela Vincent
Journal:  Brain       Date:  2011-12       Impact factor: 13.501

8.  Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient.

Authors:  Abhishek Saxena; Jo Stevens; Hakan Cetin; Inga Koneczny; Richard Webster; Konstantinos Lazaridis; Socrates Tzartos; Kathleen Vrolix; Gisela Nogales-Gadea; Barbie Machiels; Peter C Molenaar; Jan Damoiseaux; Marc H De Baets; Katja Simon-Keller; Alexander Marx; Angela Vincent; Mario Losen; Pilar Martinez-Martinez
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

9.  Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Authors:  Mario Losen; Aran F Labrijn; Vivianne H van Kranen-Mastenbroek; Maarten L Janmaat; Krista G Haanstra; Frank J Beurskens; Tom Vink; Margreet Jonker; Bert A 't Hart; Marina Mané-Damas; Peter C Molenaar; Pilar Martinez-Martinez; Eline van der Esch; Janine Schuurman; Marc H de Baets; Paul W H I Parren
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

Review 10.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.